Floatz logo

Deferiprone

Iron Metabolism Disease

Chiesi Canada CorpSmall moleculePhase 4 / ApprovedDormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Iron Metabolism Disease cohort.

Asset / SponsorPhaseRating
Deferasirox
Kevin H.M. Kuo, MD, MSc, FRCPC
Phase 4BBB
DESFERRIOXAMINE B
Beni-Suef University
Phase 4BBB
AMLODIPINE
Kevin H.M. Kuo, MD, MSc, FRCPC
Phase 3BB
Hydroxyurea
Beni-Suef University
Phase 2/3B
Nigella Sativa Oil
Beni-Suef University
Phase 2/3B

View all 11 →

Same molecule, other indications

Deferiprone is also rated in:

beta-thalassemia majorActive
BBB
Indicative · Phase 4
77 / 100
View asset →
hemosiderosisDormant
BB
Indicative · Phase 4
71 / 100
View asset →
iron poisoningDormant
BB
Indicative · Phase 3
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →